tourmalinebio.com - TRML Net Assets per Single Share

Graphic logo of Tourmaline Bio, Inc. (TRML)

The market price visualization for Tourmaline Bio, Inc. (TRML) demonstrates the quotes of a biotech firm developing therapies to combat autoimmune pathologies, aiming to capture the niche of rare rheumatological diseases. The current figure stands at 10.05, while the company lacks a stable cash flow and relies on venture capital investments. Growth potential is based on the test results of the TOUR006 antibody and strategic collaborations.

Tourmaline Bio Inc (TRML): Share Book Value from 02/21/2024 to 11/08/2025

tourmalinebio.com - analytical breakdowns and key metrics (TRML)

- price and consensus price forecast:
Price Chart Tourmaline Corp|TRML - Consensus Target
- market capitalization data:
Market Value Tourmaline Bio, Inc.|TRML - Total Company Value
- book capitalization data:
Net Assets per Single Share Tourmaline Bio|TRML - Net Asset Value|Market Capitalization to Book Value Ratio tourmalinebio.com|TRML - Aggregate Asset Value
- debt and liquidity data:
Total Debt to Capital Tourmaline Bio, Inc.|TRML - Long-Term Debt to Capital|Short-Term Debt to Equity Tourmaline Bio|TRML - Aggregate Debt Obligations|Debt to Book Capitalization Ratio Tourmaline Bio, Inc.
Fundamental company valuation:Tourmaline Corp - TRML
Manufactured products of Tourmaline Bio

Investors view Tourmaline Bio, Inc. (TRML) as a promising biotech firm with high risk prior to commercialization. This metric determines the share of net assets per share after deducting all liabilities. The price action in the book value per share reflects the market consensus regarding the issuer's material stability. For Tourmaline Bio, Inc. (TRML), growth in this indicator serves as a defensive buffer, offsetting the lack of revenue during Phase 2 clinical trials. Accumulating capital on the balance sheet minimizes bankruptcy risk before the drug reaches the market.

Competitors of Tourmaline Bio, Inc. (TRML)

ARGX: Net Assets per Single Share|BNTX: Accounting Value per Share|Abivax Corp (ABVX) - Net Assets per Single Share|ADMA (admabiologics.com) - Net Assets per Single Share|Net Assets per Single Share Protagonist PTGX|Share Book Value Immunovant Inc|Kiniksa Pharmaceuticals Ltd (KNSA) - Book Value per Share|Accounting Value of a Share Grifols Biemat (GRFS)|Book Value per Share ADPT (Adaptive Biotechnologies)|celldex.com - Book Value per Share|Net Assets per Single Share Aurinia Pharmaceuticals Inc. (AUPH)|BCRX: Accounting Value of a Share|VERA (Vera Pharma) - Net Assets per Single Share|Dianthus Corp (DNTH) - Accounting Value per Share|PHVS (Pharvaris N.V.) - Book Value per Share|Book Value per Share AbCellera Corp (ABCL)|Precigen (PGEN) - Accounting Value per Share|Accounting Value of a Share Pharming Group NV (PHAR)|Book Value per Share NKTR|Upstream Pharma - Net Assets per Share|ZBIO: Net Assets per Single Share|IMNM: Accounting Value per Share|GOSS (Gossamer Bio) - Net Assets per Single Share|Accounting Value per Share KalVista Pharma|SEPN (Septerna Corp) - Accounting Value per Share|Book Value per Share PVLA|Net Assets per Single Share Savara Inc. SVRA|Equity per Share rigel.com (RIGL)|ANAB: Book Value per Share|ATXS - Net Asset Value per Share|Accounting Value per Share enGene Bio ENGN|RAPT: Book Price of a Share|Net Assets per Single Share JBIO|Net Asset Value per Share aclaristx.com|KYTX (Kyverna Therapeutics, Inc.) - Accounting Value per Share|Book Value per Share TLSA|Cabaletta Bio, Inc (CABA) - Net Assets per Single Share|Accounting Value of a Share VTYX (Ventyx Biosciences, Inc)|Theratechnologies Inc. - Net Assets per Single Share|Accounting Value per Share avalotx.com AVTX|Eledon Pharmaceuticals, Inc. - Book Value per Share|AGEN: Book Value per Share|Climb Bio, Inc. (CLYM) - Net Assets per Single Share|Zura Bio Ltd (ZURA) - Net Assets per Single Share|ATYR: Book Value per Share|Net Assets per Share ADAG|Net Assets per Single Share ImageneBio Inc IMA|Equity per Share shattucklabs.com (STTK)|EQ: Book Value per Share|CNTB - Net Asset Value per Share|Accounting Value per Share Immunic Inc (IMUX)|ATRA - Accounting Value of a Share|inflarx.de (IFRX) - Book Value per Share|X4 Pharmaceuticals Inc. (XFOR) - Net Assets per Single Share|ACET: Book Value per Share|Net Assets per Share CELU|INmune Bio, Inc. - Net Assets per Single Share|Net Asset Value per Share barinthusbio.com BRNS|Accounting Value per Share Kezar Life Sciences, Inc.|Accounting Value of a Share SAB Biotherapeutics Inc. SABS|Book Value per Share AKTX (Akari Therapeutics plc)|ENLV: Net Assets per Share|Net Assets per Single Share q32bio.com|geovax.com (GOVX) - Equity per Share|Book Value per Share EDSA|Accounting Value per Share iBio Inc (IBIO)|CARM (Carisma Therapeutics) - Accounting Value per Share|Net Assets per Share XTL Bio XTLB|Accounting Value per Share Bolt Biotherapeutics, Inc. (BOLT)|HCW Biologics, Inc. - Book Price of a Share|Net Assets per Single Share Aptevo (APVO)|AIM: Accounting Value of a Share|ADTX (aditxt.com) - Net Assets per Single Share|GRI (GRI Bio Corporation) - Accounting Value per Share|Net Assets per Single Share XORTX Therapeutics Inc.|Net Assets per Single Share HIND|REVB - Net Assets per Single Share|Share Book Value Indaptus Therapeutics Inc (INDP)|Book Value per Share Scinai|Accounting Value of a Share CalciMedica Inc CALI|Affimed Therapeutics - Book Value per Share|ALLK: Book Value per Share|Net Assets per Single Share hookipapharma.com HOOK|IGMS (IGM Biosciences) - Accounting Value of a Share|Net Assets per Single Share ITOS|Accounting Value per Share Ocean Biomedical Corp|Book Value per Share TCBP|Book Value per Share thirdharmonicbio.com THRD